Significant Ownership of ORBIMED ADVISORS LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for ORBIMED ADVISORS LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Carl L. Gordon - Carl L. Gordon/Member
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow ORBIMED ADVISORS LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from ORBIMED ADVISORS LLC
Significant Ownership of ORBIMED ADVISORS LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | COMMON STOCK | 17% | $22,703,928 | +$10,312,500 | 4,127,987 | +83% | ORBIMED ADVISORS LLC | 28 May 2026 |
| PRLD | Prelude Therapeutics Inc | COMMON STOCK | 16% | $44,259,932 | 12,935,071 | ORBIMED ADVISORS LLC | 21 Apr 2026 | ||
| EWTX | Edgewise Therapeutics, Inc. | Common Stock | 14% | $234,894,152 | 15,252,867 | ORBIMED ADVISORS LLC | 09 May 2025 | ||
| ELVN | Enliven Therapeutics, Inc. | COMMON STOCK | 13% | $140,468,212 | 7,918,163 | ORBIMED ADVISORS LLC | 16 Jun 2025 | ||
| IMA | ImageneBio, Inc. | COMMON STOCK | 13% | $7,475,225 | 1,495,045 | ORBIMED ADVISORS LLC | 14 Apr 2026 | ||
| TRAW | Traws Pharma, Inc. | Common Stock | 12% | $3,431,754 | +$2,040,131 | 1,876,198 | +147% | ORBIMED ADVISORS LLC | 16 Apr 2026 |
| CRVS | CORVUS PHARMACEUTICALS, INC. | COMMON STOCK | 10% | $66,290,001 | -$9,057,756 | 8,609,091 | -12% | ORBIMED ADVISORS LLC | 23 Jan 2026 |
| XLO | Xilio Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 10% | $5,399,220 | 642,000 | ORBIMED ADVISORS LLC | 31 Mar 2026 | ||
| STTK | Shattuck Labs, Inc. | Common Stock, par value $0.0001 per share | 10% | $5,107,963 | 6,306,127 | ORBIMED ADVISORS LLC | 25 Aug 2025 | ||
| CMPX | Compass Therapeutics, Inc. | COMMON STOCK | 8.9% | $41,093,984 | 15,219,994 | 0% | ORBIMED ADVISORS LLC | 13 Aug 2025 | |
| WHWK | Whitehawk Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 8.9% | $6,415,640 | 4,166,000 | OrbiMed Advisors LLC | 31 Mar 2025 | ||
| ACET | Adicet Bio, Inc. | Common Stock, par value $0.0001 | 8.8% | $7,113,107 | -$117,272,169 | 844,787 | -94% | ORBIMED ADVISORS LLC | 08 Apr 2026 |
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 8% | $3,763,800 | 510,000 | ORBIMED ADVISORS LLC | 31 Dec 2024 | ||
| MBX | MBX Biosciences, Inc. | COMMON STOCK | 7.7% | $118,413,222 | -$11,880,750 | 3,637,887 | -9.1% | ORBIMED ADVISORS LLC | 05 Feb 2026 |
| AVBP | ArriVent BioPharma, Inc. | Common Stock | 7.5% | $66,692,036 | 3,027,328 | ORBIMED ADVISORS LLC | 11 Aug 2025 | ||
| NSPR | InspireMD, Inc. | Common Stock, par value $0.0001 per share | 7.4% | $5,577,461 | +$1,780,000 | 3,133,405 | +47% | ORBIMED ADVISORS LLC | 31 Dec 2025 |
| IKNA | ImageneBio, Inc. | COMMON STOCK | 6.9% | $820,179 | -$7,669,269 | 773,754 | -90% | ORBIMED ADVISORS LLC | 25 Jul 2025 |
| SION | Sionna Therapeutics, Inc. | Common Stock | 6.6% | $118,970,633 | -$29,554,504 | 2,967,722 | -20% | ORBIMED ADVISORS LLC | 15 Apr 2026 |
| NPCE | NeuroPace Inc | Common Stock, par value $0.001 per share | 6.2% | $27,569,330 | -$6,807,190 | 2,096,527 | -20% | OrbiMed Advisors LLC | 31 Mar 2026 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | Common Stock, par value $0.0001 per share | 5.9% | $5,307,498 | 718,200 | OrbiMed Capital LLC | 31 Dec 2024 | ||
| CYBN | Cybin Inc. | Common Stock, no par value | 4.9% | 2,422,600 | ORBIMED CAPITAL LLC | 31 Dec 2025 | |||
| TERN | Terns Pharmaceuticals, Inc. | Common Stock | 4.8% | $31,842,911 | 4,240,068 | ORBIMED ADVISORS LLC | 03 Nov 2025 | ||
| IRON | Disc Medicine, Inc. | Common Stock | 4.5% | $73,382,798 | 1,556,369 | ORBIMED ADVISORS LLC | 10 Mar 2025 | ||
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 4.3% | 884,230 | ORBIMED ADVISORS LLC | 31 Mar 2026 | |||
| PASG | Passage BIO, Inc. | COMMON STOCK | 4.2% | $53,029 | -$44,595 | 132,473 | -46% | ORBIMED ADVISORS LLC | 22 Jul 2025 |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.2% | $1,213,378 | 1,639,700 | 0% | ORBIMED CAPITAL LLC | 31 Dec 2025 | |
| ADCT | ADC Therapeutics SA | Common Shares, par value CHF 0.08 per share | 2.6% | $11,953,949 | -$765,959 | 3,230,797 | -6% | ORBIMED CAPITAL LLC | 31 Dec 2025 |
| VSTM | Verastem, Inc. | Common Stock, par value $0.0001 per share | 2.4% | $6,319,998 | -$7,248,005 | 1,333,333 | -53% | ORBIMED ADVISORS LLC | 30 Jun 2025 |
| CTMX | CytomX Therapeutics, Inc. | Common Stock, par value $0.00001 per share | 2.1% | $15,160,295 | -$21,224,155 | 3,525,650 | -58% | OrbiMed Advisors LLC | 31 Dec 2025 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock, par value $0.001 per share | 2.1% | $6,847,128 | -$10,261,865 | 475,165 | -60% | OrbiMed Advisors LLC | 31 Mar 2026 |
| XFOR | X4 Pharmaceuticals, Inc | Common Stock, par value $0.001 per share | 1.7% | $25,640 | 134,947 | ORBIMED ADVISORS LLC | 30 Jun 2025 | ||
| CCCC | C4 Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 1% | $1,687,550 | -$5,127,991 | 883,534 | -75% | OrbiMed Capital LLC | 31 Dec 2025 |
| PMVP | PMV Pharmaceuticals, Inc. | COMMON STOCK | 0% | $0 | -$6,219,114 | 0 | -100% | ORBIMED ADVISORS LLC | 02 Mar 2026 |
| RAPT | RAPT Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | -$1,130,083 | 0 | -100% | ORBIMED ADVISORS LLC | 31 Mar 2026 |
| XTNT | Xtant Medical Holdings, Inc. | COMMON STOCK | 0% | $0 | 0 | ORBIMED ADVISORS LLC | 10 Apr 2025 |
Schedules 13D/G Reported by ORBIMED ADVISORS LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.